Details

Autor(en) / Beteiligte

• Bertagnolli, Monica M
• Eagle, Craig J
• Zauber, Ann G
• Redston, Mark
• Solomon, Scott D
• Kim, KyungMann
• Tang, Jie
• Rosenstein, Rebecca B
• Wittes, Janet
• Corle, Donald
• Hess, Timothy M
• Woloj, G. Mabel
• Boisserie, Frédéric
• Anderson, William F
• Viner, Jaye L
• Bagheri, Donya
• Burn, John
• Chung, Daniel C
• Dewar, Thomas
• Foley, T. Raymond
• Hoffman, Neville
• Macrae, Finlay
• Pruitt, Ronald E
• Saltzman, John R
• Salzberg, Bruce
• Sylwestrowicz, Thomas
• Gordon, Gary B
• Hawk, Ernest T

Titel

Celecoxib for the Prevention of Sporadic Colorectal Adenomas

Ist Teil von

• The New England journal of medicine, 2006-08, Vol.355 (9), p.873-884

Ort / Verlag

Boston, MA: Massachusetts Medical Society

Erscheinungsjahr

2006

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• In this placebo-controlled trial of patients who had had colonic adenomas removed before study entry, celecoxib reduced the risk of recurrence of adenomas after three years of treatment (risk ratio, 0.67 for 200 mg of celecoxib twice daily and 0.55 for 400 mg of celecoxib twice daily) and increased the risk of serious cardiovascular events (risk ratio, 2.6 and 3.4, respectively). Celecoxib reduced the risk of recurrence of adenomas after three years of treatment and increased the risk of serious cardiovascular events. Colorectal cancer is a common malignant condition, responsible for approximately 150,000 new patients and approximately 55,000 deaths per year in the United States alone. 1 Despite these statistics, colorectal cancer is one of the most preventable cancers. Most colorectal cancers develop from precursor adenomas, which can be identified and removed during a screening colonoscopy. This procedure may lower the rates of death due to colorectal cancer by as much as 30 to 40 percent. 2 The aim of chemoprevention is to use pharmacologic agents to augment the benefits of colonoscopic polypectomy by inhibiting early stages of tumorigenesis, thereby preventing malignant transformation of . . .